主页文献库搜索
Is there evidence of diminishing disparities in treatment (tx) with adjuvant ...

Davidoff(A J),Choti(M A),Zuckerman(I H),Ob... J Clin Oncol 0000-00-00

...mos of diagnosis. Logistic regression estimated effects of race, age, income, Medicaid enrollment, urban residence and y...

Survival of lung surgery patients with pulmonary metastases from colonic neop...

Tampellini(M),Alabiso(I),Ottone(A),Miragli... J Clin Oncol 0000-00-00

...mos (p<0.001). Overall survivals (OS) were (mos): 29.6, 23.8, 31.2, 67.2, 59.5+ for Overall, G1, G2, G3, and G4, respect...

Lumiliximab in combination with FCR for the treatment of relapsed chronic lym...

Byrd(J C),Castro(J E),Flinn(I W),Forero-To... J Clin Oncol 0000-00-00

...mos. Median PFS for all responders and CR pts were 23.4 mos and 30.4 mos, respectively. Twenty-three pts (74%) reported ...

Bosutinib is safe and active in patients (pts) with chronic phase (CP) chroni...

Bruemmendorf(T H),Cervantes(F),Kim(D),Chan... J Clin Oncol 0000-00-00

...mos (range 0.03-19.5 mos). Prior therapy in addition to imatinib, included interferon (58 pts), dasatinib and/or nilotin...

Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cycloph...

Rai(K R),Moore(J),Wu(J),Novick(S C),O&#x27;Brie... J Clin Oncol 0000-00-00

...mos] versus FC [22 mos]) (P=0.031). In both groups, CR was associated with relief from all predefined CLL symptoms for ≥...

Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous ...

Mauro(M J),Baccarani(M),Cervantes(F),Lipto... J Clin Oncol 0000-00-00

...mos. Progression-free survival (PFS) at 24 mos was 80% (75% in imatinib-resistant and 94% in imatinib-intolerant pts). O...

Imatinib mesylate is effective in the treatment of polycythemia vera: A multi...

Feldman(E J),Spivak(J L),Lee(S),Rivera(M),... J Clin Oncol 0000-00-00

...mos; average number of PHLs per year ranged from 0-23 (mean=9). After 1 year of imatinib, PHLs ranged from 0 to 9 (mean=...

A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to ima...

Le Coutre(P D),Ottmann(O),Gatterman(N),Lar... J Clin Oncol 0000-00-00

...mos. Three of 5 patients with data available had a Bcr-Abl mutation at baseline. HR occurred in 14 (64%) pts of which 10...

A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to ima...

Kantarjian(H M),Gattermann(N),O&#x27;Brien(S G)... J Clin Oncol 0000-00-00

...mos. BCR-ABL mutations associated with imatinib resistance were detected in 11/17 (65%) pts at baseline. The median dura...

Select high risk genetic features predict earlier progression following chemo...

Grever(M R),Dewald(G W),Neuberg(D S),Reed(... J Clin Oncol 0000-00-00

...mos versus 19.2 mos) compared to F. CR and OR were not significantly different based on interphase cytogenetics, IgV sta...

上一页 676 677 678 679 680 681 682 683 684 下一页 680 / 共 704

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]